Abstract 115P
Background
Trifluridine/tipiracil (lonsurf) and regorafenib are standard of treatment in patients with chemo-refractory metastatic colorectal cancer (mCRC). Our study aimed to investigate the impact of sidedness on survival in patients with mCRC treated with lonsurf or regorafenib.
Methods
Patients who were diagnosed with mCRC and treated with lonsurf or regorafenib between 2015 and 2022 were retrospectively identified from Taiwan National Health Insurance Research Database and Taiwan Cancer Registry. Propensity score matching was used to reduce the selection bias. The oncologic outcomes were presented with time to treatment failure (TTF) and overall survival (OS).
Results
A total of 4665 patients were identified. After matching, 752 patients were analyzed for outcomes comparison, including 376 patients in each group. In general, median TTF and OS were 1.9 months versus 2.0 months (p = 0.701)and 9.1 months versus 7.0 months (p = 0.008) in lonsurf and regorafenib, respectively. Patients were stratified by sidedness, including 297 left side mCRC in each group and 79 right side mCRC in each group. For patients with left side colon, median TTF and OS were 1.9 months versus 2.0 months (p = 0.178) and 10.2 months versus 7.8 months (p = 0.006) in lonsurf and regorafenib, respectively, while for patients with right side colon, median TTF and OS were 1.8 months versus 1.8 months (p = 0.390) and 7.8 months versus 6.0 months (p = 0.011) in lonsurf and regorafenib, respectively.
Conclusions
Lonsurf provided a longer survival over regorafenib in mCRC patients regardless of sidedness of primary tumor location.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
16P - Patient and healthcare practitioner preferences in early-stage triple-negative breast cancer treatment: A discrete choice experiment
Presenter: Jiun-I Lai
Session: Poster Display
Resources:
Abstract
17P - Initial outcomes of the ACT Now PRIME CARE for breast cancer: Prevention of Breast canceR (screening/ stage shifting) utilizing Integrated MobilE Clinics and pAtient Reported online Evaluations and Education
Presenter: Herdee Gloriane Luna
Session: Poster Display
Resources:
Abstract
18P - Optimizing premenopausal HR+ HER2–ve eBC management in India: Insights from expert consensus
Presenter: Anitha Ramesh
Session: Poster Display
Resources:
Abstract
19P - Referral patterns among breast cancer patients in county-level hospitals in China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
20P - Real-world treatment of HER2+ and HR+/HER2- early breast cancer in county areas of China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
21P - Duration of breast cancer trials: Analysis of predicted versus actual completion date
Presenter: Daniëlle Verschoor
Session: Poster Display
Resources:
Abstract
22P - Impact of an online Asian genetic risk calculator on risk perception: Cancer-related distress and uptake of genetic counselling among Malaysian breast cancer patients (The ARiCa Study)
Presenter: HEAMANTHAA Padmanabhan
Session: Poster Display
Resources:
Abstract
23P - Consensus statements and expert recommendations for BRCAm breast cancer in the Asia-Pacific region (STREAM-AP)
Presenter: Soo Chin Lee
Session: Poster Display
Resources:
Abstract
24P - Germline genetic testing for hereditary cancer: A retrospective analysis in a single site referral centre in Malaysia
Presenter: Vivian Lee
Session: Poster Display
Resources:
Abstract
25P - Clinical presentations and prognostication of HER2-low breast cancer in Taiwan
Presenter: Bo-Fang Chen
Session: Poster Display
Resources:
Abstract